$ANIX

COPYTELE INC

CIK:0000715446|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2026	Jul. 31, 2025	Jul. 31, 2026	Jul. 31, 2025
Income Statement [Abstract]
Revenue
Operating expenses:
Research and development expenses (including non-cash stock-based compensation expenses of $286, $358, $909 and $1,172, respectively)	1,326	1,055	3,686	3,929
General and administrative expenses (including non-cash stock-based compensation expenses of $380, $497, $1,218 and $1,727, respectively)	1,411	1,381	4,414	4,896
Total operating expenses	2,737	2,436	8,100	8,825
Loss from operations	(2,737)	(2,436)	(8,100)	(8,825)
Interest income	112	156	354	519
Net loss	(2,625)	(2,280)	(7,746)	(8,306)
Less: Net loss attributable to noncontrolling interest	(19)	(22)	(59)	(74)
Net loss attributable to common shareholders	$ (2,606)	$ (2,258)	$ (7,687)	$ (8,232)
Net loss per common share attributable to common shareholders:
Basic	$ (0.08)	$ (0.07)	$ (0.23)	$ (0.25)
Diluted	$ (0.08)	$ (0.07)	$ (0.23)	$ (0.25)
Weighted average common shares outstanding:
Basic	34,182	32,476	33,673	32,293
Diluted	34,182	32,476	33,673	32,293

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Jul. 31, 2026	Jul. 31, 2025
Reconciliation of net loss to net cash used in operating activities:
Net loss	$ (7,746)	$ (8,306)
Stock option compensation to employees and directors	2,042	2,822
Stock options issued to consultants	85	77
Amortization of operating lease right-of-use asset	30	27
Change in amortization of discount on held-to-maturity securities	59	(93)
Change in operating assets and liabilities:
Receivables		173
Prepaid expenses and other current assets	(334)	(155)
Accounts payable	117	(249)
Accrued expenses	(344)	(195)
Operating lease liability	(30)	(19)
Net cash used in operating activities	(6,121)	(5,918)
Cash flows from investing activities:
Disbursements to acquire short-term investments	(34,418)	(36,700)
Proceeds from maturities of short-term investments	35,823	40,912
Net cash provided by investing activities	1,405	4,212
Cash flows from financing activities:
Proceeds from sale of common stock in an at-the-market offering, net of offering expenses of $207 and $123, respectively	4,806	1,924
Proceeds from sale of common stock pursuant to an employee stock purchase plan	4	4
Proceeds from exercise of stock options	60	2
Net cash provided by financing activities	4,870	1,930
Net increase in cash and cash equivalents	154	224
Cash and cash equivalents at beginning of period	1,244	1,271
Cash and cash equivalents at end of period	$ 1,398	$ 1,495

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jul. 31, 2026	Oct. 31, 2025
Current assets:
Cash and cash equivalents	$ 1,398	$ 1,244
Short-term investments	12,466	13,930
Prepaid expenses and other current assets	1,047	713
Total current assets	14,911	15,887
Operating lease right-of-use asset	163	193
Total assets	15,074	16,080
Current liabilities:
Accounts payable	282	165
Accrued expenses	1,417	1,761
Operating lease liability, current	46	41
Total current liabilities	1,745	1,967
Operating lease liability, non-current	128	163
Total liabilities	1,873	2,130
Commitments and contingencies (Note 10)
Shareholders’ equity:
Preferred stock, value
Common stock, par value $.01 per share; 100,000,000 shares authorized; 34,584,538 and 33,013,829 shares issued and outstanding as of July 31, 2026 and October 31, 2025, respectively	346	330
Additional paid-in capital	273,489	266,508
Accumulated deficit	(259,364)	(251,677)
Total shareholders’ equity	14,471	15,161
Noncontrolling interest (Note 2)	(1,270)	(1,211)
Total equity	13,201	13,950
Total liabilities and equity	15,074	16,080
Series A Convertible Preferred Stock [Member]
Shareholders’ equity:
Preferred stock, value